EGFR and laryngotracheoesophageal cleft: EGFR polymorphisms, as a form of genetic variation in addition to EGFR mutations, have been reported to correlate with the prognosis of survival in patients with EGFR mutation-positive LC treated with tyrosine kinase inhibitors (TKIs) (Oxnard et al., 2011; Leonetti et al., 2019; He et al., 2021), and some studies (Bashir et al., 2019; Liu et al., 2015; Feng et al., 2014; Li et al., 2023; Bashir et al., 2018) have shown an association with susceptibility in LC patients.